285 related articles for article (PubMed ID: 34542912)
1. Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
Lake J; Reed X; Langston RG; Nalls MA; Gan-Or Z; Cookson MR; Singleton AB; Blauwendraat C; Leonard HL;
Mov Disord; 2022 Jan; 37(1):95-105. PubMed ID: 34542912
[TBL] [Abstract][Full Text] [Related]
2. Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
Bryant N; Malpeli N; Ziaee J; Blauwendraat C; Liu Z; ; West AB
Hum Mol Genet; 2021 Apr; 30(6):454-466. PubMed ID: 33640967
[TBL] [Abstract][Full Text] [Related]
3. Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
Heckman MG; Labbé C; Kolicheski AL; Soto-Beasley AI; Walton RL; Valentino RR; Brennan ER; Johnson PW; Baheti S; Sarangi V; Ren Y; Uitti RJ; Wszolek ZK; Ross OA
Parkinsonism Relat Disord; 2021 Feb; 83():22-30. PubMed ID: 33454605
[TBL] [Abstract][Full Text] [Related]
4. Functional variants in the
Hui KY; Fernandez-Hernandez H; Hu J; Schaffner A; Pankratz N; Hsu NY; Chuang LS; Carmi S; Villaverde N; Li X; Rivas M; Levine AP; Bao X; Labrias PR; Haritunians T; Ruane D; Gettler K; Chen E; Li D; Schiff ER; Pontikos N; Barzilai N; Brant SR; Bressman S; Cheifetz AS; Clark LN; Daly MJ; Desnick RJ; Duerr RH; Katz S; Lencz T; Myers RH; Ostrer H; Ozelius L; Payami H; Peter Y; Rioux JD; Segal AW; Scott WK; Silverberg MS; Vance JM; Ubarretxena-Belandia I; Foroud T; Atzmon G; Pe'er I; Ioannou Y; McGovern DPB; Yue Z; Schadt EE; Cho JH; Peter I
Sci Transl Med; 2018 Jan; 10(423):. PubMed ID: 29321258
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A case-control association study for Parkinson's disease.
Gopalai AA; Lim JL; Li HH; Zhao Y; Lim TT; Eow GB; Puvanarajah S; Viswanathan S; Norlinah MI; Abdul Aziz Z; Lim SK; Tan CT; Tan AH; Lim SY; Tan EK; Ahmad Annuar A
Mol Genet Genomic Med; 2019 Nov; 7(11):e604. PubMed ID: 31487119
[TBL] [Abstract][Full Text] [Related]
6. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
[TBL] [Abstract][Full Text] [Related]
7. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
Usenko TS; Senkevich KA; Basharova KS; Bezrukova AI; Baydakova GV; Tyurin AA; Beletskaya MV; Kulabukhova DG; Grunina MN; Emelyanov AK; Miliukhina IV; Timofeeva AA; Zakharova EY; Pchelina SN
Gene; 2023 Oct; 882():147639. PubMed ID: 37473971
[TBL] [Abstract][Full Text] [Related]
8. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
[TBL] [Abstract][Full Text] [Related]
9. Identification of Targets from LRRK2 Rescue Phenotypes.
Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.
Heckman MG; Elbaz A; Soto-Ortolaza AI; Serie DJ; Aasly JO; Annesi G; Auburger G; Bacon JA; Boczarska-Jedynak M; Bozi M; Brighina L; Chartier-Harlin MC; Dardiotis E; Destée A; Ferrarese C; Ferraris A; Fiske B; Gispert S; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lin CH; Lohmann K; Loriot MA; Lynch T; Mellick GD; Mutez E; Opala G; Park SS; Petrucci S; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Tomiyama H; Uitti RJ; Valente EM; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Xiromerisiou G; Maraganore DM; Farrer MJ; Ross OA;
Neurobiol Aging; 2014 Jan; 35(1):266.e5-14. PubMed ID: 23962496
[TBL] [Abstract][Full Text] [Related]
11. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
[TBL] [Abstract][Full Text] [Related]
12. Linking a genome-wide association study signal to a LRRK2 coding variant in Parkinson's disease.
Foo JN; Chung SJ; Tan LC; Liany H; Ryu HS; Hong M; Koh TH; Irwan ID; Au WL; Prakash KM; Aung T; Cheng CY; Chong SA; Khor CC; Lee J; Tai ES; Vithana EN; Wong TY; Song K; Liu J; Tan EK
Mov Disord; 2016 Apr; 31(4):484-7. PubMed ID: 26687033
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 variation and dementia with Lewy bodies.
Heckman MG; Soto-Ortolaza AI; Contreras MYS; Murray ME; Pedraza O; Diehl NN; Walton R; Labbé C; Lorenzo-Betancor O; Uitti RJ; van Gerpen J; Ertekin-Taner N; Smith GE; Kantarci K; Savica R; Jones DT; Graff-Radford J; Knopman DS; Lowe VJ; Jack CR; Petersen RC; Parisi JE; Rademakers R; Wszolek ZK; Graff-Radford NR; Ferman TJ; Dickson DW; Boeve BF; Ross OA
Parkinsonism Relat Disord; 2016 Oct; 31():98-103. PubMed ID: 27521182
[TBL] [Abstract][Full Text] [Related]
14. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
[TBL] [Abstract][Full Text] [Related]
15. Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score.
Iwaki H; Blauwendraat C; Makarious MB; Bandrés-Ciga S; Leonard HL; Gibbs JR; Hernandez DG; Scholz SW; Faghri F; ; Nalls MA; Singleton AB
Mov Disord; 2020 May; 35(5):774-780. PubMed ID: 31958187
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder.
Ouled Amar Bencheikh B; Ruskey JA; Arnulf I; Dauvilliers Y; Monaca CC; De Cock VC; Gagnon JF; Spiegelman D; Hu MTM; Högl B; Stefani A; Ferini-Strambi L; Plazzi G; Antelmi E; Young P; Heidbreder A; Mollenhauer B; Sixel-Döring F; Trenkwalder C; Oertel W; Montplaisir JY; Postuma RB; Rouleau GA; Gan-Or Z
Parkinsonism Relat Disord; 2018 Jul; 52():98-101. PubMed ID: 29576439
[TBL] [Abstract][Full Text] [Related]
17. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
Dzamko N; Rowe DB; Halliday GM
Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
19. Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.
Coku I; Mutez E; Eddarkaoui S; Carrier S; Marchand A; Deldycke C; Goveas L; Baille G; Tir M; Magnez R; Thuru X; Vermeersch G; Vandenberghe W; Buée L; Defebvre L; Sablonnière B; Chartier-Harlin MC; Taymans JM; Huin V
Mov Disord; 2022 Aug; 37(8):1761-1767. PubMed ID: 35708213
[TBL] [Abstract][Full Text] [Related]
20. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
